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Randomised controlled trial comparing POCT with standard 
3 
 
clinical care, in adults presenting to secondary care with 
acute respiratory illness (ResPOC Trial). 
Countries of recruitment  UK 
Health condition Acute respiratory illness 
Intervention Point-of-care testing with a molecular test for respiratory 
viruses 
Control Routine clinical care 
Inclusion criteria 1. Aged 18 years or over. 
2. Has the capacity to give informed, written consent  
3. Is a patient in Southampton General Hospital Acute 
Medical Unit or Emergency Department  
4. Can be recruited to the study within 24 hours of 
presentation to hospital 
5. Has an acute respiratory illness and / or fever >37.5°C 
6. Duration of illness less than or equal to 7 days 
Exclusion criteria 1. Patients not fulfilling inclusion criteria 
2. A palliative approach being taken by the treating clinicians 
3. Previously included in this study and re-presenting within 
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the last 30 days after hospital discharge 
4. Declines nasal / pharyngeal swabbing 
Study type  Randomised controlled trial 
Open label, Parallel group with 1:1 allocation to intervention 
and control groups. 
Randomisation Internet based random sequence allocation using random 
permuted blocks (sealedenvelope.com) 
Date of first enrolment 15th January 2015 
Date of last enrolment  30th April 2016 
Target sample size 720 
Recruitment status Completed 
Primary Outcome Proportion of patients treated with antibiotics during 
hospitalisation (up to 30 days) 
Key secondary outcomes* 1. Duration of antibiotic use, days 
2. Proportion of patients treated with less than 48 hours of 
antibiotics  
3. Proportion of influenza positive patients treated with 
antivirals 
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4. Proportion of antiviral use occurring in patients with 
influenza  
5. Duration of antivirals, hours  
6. Speed of administration of antivirals, hours 
7. Proportion of patients admitted to a side room  
8. Duration of side room use, days 
10. Time to isolation and de-isolation , days 
11. Turnaround time of testing, minutes  
12. Proportion of patients with viruses detected 
13. Length of hospital stay , days 
*All secondary outcome measures relate to the period of 
hospitalisation (up to 30 days) 
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ABSTRACT 12 
Background 13 
Respiratory viruses are associated with a huge socio-economic burden and are responsible for a 14 
large proportion of acute respiratory illness in hospitalised adults. Laboratory PCR is accurate but 15 
takes at least 24 hours to generate a result to clinicians and antigen-based point-of-care tests (POCT) 16 
lack sensitivity. Rapid molecular platforms, such as the FilmArray Respiratory Panel, have equivalent 17 
diagnostic accuracy to laboratory PCR and can generate a result in 1 hour making them deployable 18 
as POCT. Molecular point-of-care testing for respiratory viruses in hospital has the potential to 19 
improve the detection rate of respiratory viruses, improve the use of influenza antivirals and reduce 20 
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unnecessary antibiotic use,  but high quality randomised trials with clinically relevant endpoints are 1 
needed. 2 
Methods 3 
The ResPOC study is a pragmatic randomised controlled trial of molecular point-of-care testing for 4 
respiratory viruses in adults with acute respiratory illness presenting to a large teaching hospital in 5 
the United Kingdom. Eligible participants are adults presenting with acute respiratory illness to the 6 
emergency department or the acute medicine unit. Participants are allocated 1:1 by internet-based 7 
randomisation service to either the intervention of a nose and throat swab analysed immediately on 8 
the FilmArray Respiratory Panel as a POCT or receive routine clinical care. The primary outcome is 9 
the proportion of patients treated with antibiotics. Secondary outcomes include turnaround time, 10 
virus detection, neuraminidase inhibitor use, length of hospital stay and side room use. Analysis of 11 
the primary outcome will be by intention-to-treat and all enrolled participants will be included in 12 
safety analysis.  13 
Discussion 14 
Multiple novel molecular POCT platforms for infections including respiratory viruses have been 15 
developed and licensed in the last few years and many more are in development but the evidence 16 
base for clinical benefit above standard practice is minimal. This randomised controlled trial aims to 17 
close this evidence gap by generating high quality evidence for the clinical impact of molecular POCT 18 
for respiratory viruses in secondary care and to act as an exemplar for future studies of molecular 19 
POCT for infections. This study has the potential to change practice and improve patient care for 20 
patients presenting to hospital with acute respiratory illness. 21 
Trial Registration 22 
This study was registered with ISRCTN, number ISRCTN90211642, on 14th January 2015. 23 
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INTRODUCTION 3 
Background and rationale 4 
Respiratory virus burden of disease 5 
Respiratory tract infections are the second most common cause of mortality and morbidity 6 
worldwide [1] and viruses are the most frequently detected pathogens in acute respiratory illness 7 
[2]. The influenza virus causes seasonal epidemics leading to excess hospitalisations and death 8 
mainly in the elderly and in patients with co-morbidity [3,4]. Annual seasonal influenza vaccine is 9 
recommended in at risk groups [5–7] however vaccine uptake is sub-optimal [8,9] and high quality 10 
evidence for significant protection in the elderly is lacking [10,11]. 11 
The rate of hospitalisation in adults with influenza has been estimated at 5 to 20 per 100,000 overall 12 
[12,13] and may be as high as 1200 per 100,000 in those over 85 years old [4]. Hospitalisation and 13 
death result from the complications of influenza including pneumonia and exacerbation of 14 
underlying cardiopulmonary conditions [14]. In adults, patients hospitalised with laboratory 15 
confirmed influenza, 10-30% are admitted to critical care units and 3-15% die in hospital [15–17] 16 
with outcomes being predicted by co-morbidity [17,18]. Estimates of the burden of influenza virus 17 
infection in hospitalised adults have traditionally been based on the incidence of the influenza-like-18 
illness syndrome (ILI, defined as fever of >38°C and new respiratory symptoms) rather than on 19 
laboratory confirmed influenza. ILI has poor sensitivity (around 50%) and specificity (0-63%) for the 20 
diagnosis of influenza in hospitalised adults even during periods of peak activity [19–22]. Where 21 
estimates of disease burden are based on laboratory confirmed influenza, laboratory testing of 22 
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patients is based on clinical suspicion of influenza and is generally targeted to patients with 1 
respiratory symptoms and fever. However, in addition to acute respiratory presentations, influenza 2 
may present as decompensated cardiovascular disease, collapse or diabetic emergencies [23,24]. For 3 
this reason many hospitalised cases of influenza are likely to remain undiagnosed. A recent Canadian 4 
study estimated that only around 1 in 14 ED visits due to influenza virus infection were correctly 5 
attributed to influenza [25]. It is likely, therefore, that the burden of influenza and other respiratory 6 
viruses amongst hospitalised adults and its economic impact have been under-estimated. In addition 7 
to influenza viruses, other respiratory viruses including rhinovirus, respiratory syncytial virus, 8 
parainfluenza viruses, human metapneumovirus and coronaviruses, cause acute exacerbations of 9 
COPD and asthma as well as other acute respiratory presentations [2], which lead to large numbers 10 
of hospitalisations every year and significant burdens upon healthcare systems. 11 
Conventional rapid diagnostic tests 12 
Rapid diagnostic tests for influenza based on antigen detection in nasal samples have been available 13 
for many years but have been diagnostically inaccurate in adults, where sensitivity is around 50% 14 
[26,27]. The current gold standard diagnostic test for respiratory viruses is laboratory performed 15 
polymerase chain reaction (PCR) which is highly sensitive and specific but has turnaround times of at 16 
least 24 hours and requires specialist laboratory facilities and expertise [28]. New rapid, molecular 17 
tests have recently been developed, including the FilmArray Respiratory Panel. These molecular 18 
platforms are comparable in accuracy to laboratory PCR, without the need for specialist laboratory 19 
support and expertise, and can potentially be used as a point-of-care test (POCT), but the evidence 20 
for molecular POCT improving patient outcomes is weak.  21 
FilmArray Respiratory Panel 22 
The FilmArray Respiratory Panel (BioFire Diagnostics, Utah, USA, owned by bioMérieux) uses nested 23 
real-time PCR to detect 20 respiratory pathogens. The FilmArray requires only 2 minutes of “hands 24 
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on” time and produces a test result in about one hour [29]. The FilmArray Respiratory Panel is both 1 
FDA-cleared and CE IVD marked. The viral pathogens detected by the FilmArray Respiratory Panel 2 
are: Influenza A (untyped, A/H1, A/H1-2009, A/H3), Influenza B, Adenovirus, Coronaviruses (HKU1, 3 
NL63, 229E, OC43) Human Metapneumovirus, Human Rhinovirus/Enterovirus, Parainfluenza (types 4 
1, 2, 3, 4) and Respiratory Syncytial Virus. Three bacterial respiratory pathogens are also detected: 5 
Bordetella pertussis, Chlamydophila pneumoniae and Mycoplasma pneumoniae [29,30]. 6 
The FilmArray respiratory panel is broadly equivalent in accuracy to laboratory PCR, and use has 7 
been validated on nose and throat swabs, nasopharyngeal aspirates, lower respiratory tract samples, 8 
and samples from immunocompromised patients [30–36]. Initial mediocre sensitivity for adenovirus 9 
detection has been greatly improved [37]. All of these studies show favourable outcomes with 10 
FilmArray system, including reliability, accuracy, ease of use and turnaround time although these 11 
studies were conducted in a laboratory rather at the point-of-care and a disproportionate number of 12 
these studies were conducted from samples from children rather than adults. In terms of clinical 13 
impact, a study examining clinical outcomes in children has shown that use of the FilmArray reduced 14 
the duration of antibiotic use, the length of inpatient stay, and the time in isolation [38]. However, 15 
this was not a randomised controlled trial but examined outcomes pre- and post- implementation. 16 
To our knowledge, there have been no randomised controlled trials of this system as a point-of-care 17 
test examining the potential clinical and health economic benefits of this system. Although there are 18 
data to suggest clinical benefits (in terms of duration of hospital stay, number of investigations, and 19 
antibiotic use) for use of rapid diagnostic tests of influenza and other respiratory viruses in children 20 
[39–42] the clinical benefits and cost effectiveness of such a strategy in adults are unknown [43]. 21 
Point-of-care testing in the wider context 22 
The Department of Health commissioned Carter report into UK pathology services noted the 23 
importance of developing clinically relevant point-of-care diagnostic tests to reduce turnaround 24 
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times and improve patient pathways [44]. The UK Medicines and Healthcare products Regulatory 1 
Agency (MHRA) document 'Management and Use of Point-of-Care Test Devices' sets out the context 2 
in which POCT should be considered for use and provides guidelines for their successful and safe 3 
implementation [45]. The objectives of this study are in line with these documents and it aims to 4 
examine the initial phase of a POCT programme; establishing a clinical need for the test and 5 
evaluating potential clinical benefits. 6 
Alignment with global research priorities 7 
In addition to being focused on patient and health care organisation outcomes, this clinical research 8 
is strongly aligned with several global research priority initiatives including the World Health 9 
Organisation’s Battle against Respiratory Viruses Initiative (BRaVe) initiative [46] and the global 10 
report into antibiotic resistance [47]. The BRaVe initiative aims to catalyse multidisciplinary research 11 
on strategies to prevent and treat medically important respiratory virus infections with the goal of 12 
timely integration of research advances into public health practice. Priority areas identified include 13 
improving diagnostic tests for viral respiratory illness and improving the clinical management of 14 
patients with acute respiratory viral illness which are both addressed by this study.  15 
Study Aims and Objectives 16 
This study aims to prospectively evaluate whether use of a molecular point-of-care diagnostic test 17 
will improve clinical outcomes compared to routine clinical care, in adult patients presenting to the 18 
secondary care with acute respiratory illness. The primary objective of the study is to evaluate the 19 
impact of POCT on antibiotic use. The secondary objectives include evaluating the impact of POCT on 20 
influenza antiviral use, side room facility use, duration of hospitalisation and the turnaround time of 21 
results compared with standard laboratory based PCR. 22 
Trial design 23 
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This is a pragmatic randomised controlled trial with parallel groups allocated 1:1 to the intervention 1 
(POCT) and control (routine clinical care) arms. The framework is superiority. 2 
METHODS 3 
Participants, interventions and outcomes 4 
Study setting  5 
This is a single centre study based in secondary care. All patients will be recruited from the Acute 6 
Medical Unit and Emergency Department of Southampton General Hospital, University Hospital 7 
Southampton NHS Foundation Trust, Southampton, UK. 8 
Eligibility Criteria 9 
Inclusion Criteria 10 
• Aged 18 years or over 11 
• Has the capacity to give informed, written consent and is able and willing to adhere 12 
to the study procedures 13 
• Is a patient in Southampton General Hospital’s AMU or ED 14 
• Can be recruited to the study  15 
- within a 24 hour period of first triage by ED staff OR 16 
- within a 24 hour period of arrival on AMU (if admitted directly to AMU) 17 
• Has an acute respiratory illness* and / or fever >37.5°C 18 
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• Duration of illness less than or equal to 7 days 1 
*An episode of acute respiratory illness is defined as an acute pulmonary illness (including 2 
pneumonia, bronchitis and influenza-like illness) or an acute exacerbation of a chronic respiratory 3 
illness (including exacerbation of COPD, asthma or bronchiectasis). 4 
Provisional or suspected clinical diagnoses of acute respiratory illnesses are made by an AMU or ED 5 
clinician. 6 
Exclusion Criteria 7 
• Patients not fulfilling inclusion criteria 8 
• A palliative approach being taken by the treating clinicians 9 
• Previously included in this study and re-presenting within the last 30 days after 10 
hospital discharge 11 
• Declines nasal / pharyngeal swabbing 12 
Concurrent, prior or subsequent enrolment in an observational study is not necessarily an exclusion 13 
criterion; this is at the discretion of the chief investigator. 14 
Interventions 15 
For those randomised to the interventional arm 16 
A nose and throat swab will be taken by a member of research staff (doctor or nurse) according to 17 
standard protocols. Swabs are placed directly into viral transport medium. The sample is analysed on 18 
the FilmArray Respiratory Panel as per training delivered by the apparatus manufacturer. Test 19 
results are normally available in about an hour using the FilmArray Respiratory Panel. In the event of 20 
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a run failure, the analysis run will be repeated using the same sample. The FilmArray machines are 1 
located in or near the patient-care areas. The results of the test will be documented in the patient’s 2 
case notes and in the event of a pathogen being detected, a doctor from the clinical team 3 
responsible for the patient will be directly informed. The participant will also be informed of the 4 
result on the same day. 5 
For those randomised to the control group 6 
These patients will be managed using routine clinical care, as per current practice in this large 7 
teaching hospital in the United Kingdom, which is a justifiable comparator. Respiratory virus testing 8 
using laboratory PCR will be at the discretion of the responsible clinical team.  9 
For both groups 10 
A subgroup of participants may be approached for venous blood sampling and additional 11 
nasal/throat swabs to be stored for further study including immunological testing and viral 12 
sequencing. All samples will be stored devoid of participant identifiable information to protect 13 
participant confidentiality. 14 
Outcomes 15 
Primary outcome 16 
• Proportion of patients treated with antibiotics, measured retrospectively from case 17 
notes for the entire duration of hospitalisation or at 30 days, whichever is shortest 18 
Secondary outcomes 19 
 Median duration of antibiotic use, days 20 
 Proportion of patients receiving only a stat dose of antibiotics  21 
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 Proportion of patients receiving <48 hours antibiotics 1 
 Proportion of patients receiving intravenous antibiotics 2 
 Median duration of intravenous antibiotics, days 3 
 Proportion of patients with influenza treated with influenza antivirals 4 
 Proportion of influenza antiviral use occurring in patients with influenza 5 
 Median time to influenza antiviral use, hours 6 
 Median duration of influenza antivirals, days 7 
 Median duration of hospital stay, days 8 
 Proportion of patients admitted to a side room 9 
 Median duration of side room use, days 10 
 Median time to isolation or de-isolation, days 11 
 Median length of hospital stay, days 12 
 Median turnaround time of respiratory viruses testing, hours 13 
 Proportion of patients with viruses detected 14 
 Proportionate mortality in hospital and at 30 days post randomisation 15 
 Proportion admitted to Intensive care or high dependency units 16 
 Proportion re-presenting to hospital within 30 days  17 
  Proportion re-admitted to hospital within 30 days 18 
 Proportion with prolonged in-patient stay 19 
Participant timeline 20 
Patients are identified in the AMU and ED by research staff according to eligibility criteria and once 21 
written informed consent is obtained they are immediately randomised to the intervention or 22 
control group. Those randomised to the intervention groups have a nose and throat swab performed 23 
immediately by the research team and this is then tested on the Film array machine. Results are 24 
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available after approximately 1 hour and are immediately communicated to the clinical team. 1 
Clinical data is then collected retrospectively for both groups. There are no follow up visits for either 2 
group. 3 
Sample size  4 
Sample size is based upon the primary outcome measure of proportion of patients treated with 5 
antibiotics. Previous studies have demonstrated that around 75% of patients hospitalised in the UK 6 
with acute respiratory illness are treated with antibiotics [2]. Two small studies in hospitalised adult 7 
patients with acute respiratory illness have demonstrated reductions in the proportion of patients 8 
treated with antibiotics of around 10-15% in those tested for respiratory viruses [43,48]. To detect a 9 
reduction in antibiotic use from 75% to 65% with a power of 0.8 and significance level of 0.05, 326 10 
patients would be required in each group. Allowing for withdrawals in up to 10% of patients we aim 11 
to recruit 360 patients to each group (720 patients in total). 12 
Recruitment and Screening 13 
Eligible patients in the emergency department (ED) and acute medicine unit (AMU) of Southampton 14 
General Hospital will be identified by research staff who will regularly review the comprehensive IT 15 
admissions systems in each area on a daily basis. Recruitment will run from January 2015 until April 16 
2015 and from October 2015 to April 2016 in order to include the periods of peak influenza 17 
circulation for those seasons. 18 
Assignment of interventions 19 
Sequence generation, allocation concealment and implementation 20 
Once an eligible patient has been screened, and given fully informed, written consent they will be 21 
enrolled and assigned a unique participant identification number consecutively. A study team 22 
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member will then use a dedicated internet-based randomisation service (sealedenvelope.com, 1 
which uses random permuted blocks of varying sizes) to obtain a computer generated randomisation 2 
code for the patient which will assign them to either the intervention or control group. Research 3 
staff will implement the allocation sequence and assign the patients to the group based on the 4 
allocation code from sealedenvelope.com. 5 
Blinding 6 
As this is a pragmatic trial of a diagnostic device no attempt at blinding trial participants, research 7 
staff or care providers will be made. Data analysts will be blinded to group allocation. 8 
Data collection, management and analysis 9 
Data collection methods 10 
Clinical and demographic data will be collected at the time of enrolment by research staff from 11 
patient paper case notes and electronic medical records. Outcome data will be collected 12 
retrospectively by research staff from paper case notes, electronic medical records, electronic 13 
prescribing systems, and electronic radiological and laboratory results systems. Final clinical 14 
diagnosis will be based on clinical discharge coding and discharge summaries. All source data will be 15 
entered into a standardised paper case report form. Patients withdrawn from the study will have no 16 
further data collected.  17 
Data management 18 
The study will be conducted in accordance with the approved protocol, ICH GCP relevant regulations 19 
and standard operating procedures. Data will be evaluated for compliance with the protocol and 20 
accuracy in relation to source documents. Data from case report forms will be entered into a secure 21 
bespoke database at the completion of the study followed by data lock. All data will be anonymised: 22 
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volunteer participant data will be identified by a unique study number in the CRF and database. A 1 
separate confidential file containing identifiable information will be stored in a secured location in 2 
accordance with the Data Protection Act 1998. Only the Sponsor’s representative and investigators 3 
will have access to the information. 4 
Statistical methods 5 
This will be performed by a dedicated medical statistician from the University of Southampton 6 
independent from the study team. Patients tested with the rapid diagnostic test will be compared 7 
with patients treated by routine clinical care using standard descriptive and comparative statistical 8 
methods using Prism (GraphPad Software Inc; La Jolla, California) and SPSS (SPSS, Inc; Chicago, 9 
Illinois). Summaries of all baseline characteristics will be presented using means and standard 10 
deviations, medians and interquartile ranges, or frequencies and percentages, as appropriate. 11 
Analysis of the primary outcome will be by intention-to-treat and will compare the proportion of 12 
patients receiving antibiotics using the chi-square test for equality of proportions between groups. 13 
The effect of group (intervention or control) on the primary outcome will be further assessed using 14 
logistic regression to control for demographics (age, sex) and other co-variables. For secondary 15 
outcomes the intervention and control groups will be compared using chi-square tests for equality of 16 
proportions for binary data (including proportions) and using t-tests and non-parametric equivalent 17 
tests for continuous data (e.g. turnaround time) as appropriate.  18 
Monitoring 19 
Data monitoring 20 
The study was reviewed by the sponsor and felt to be of low risk on the grounds of the non-CTIMP 21 
nature and the low likelihood of harms associated with the intervention. Therefore the creation of a 22 
data monitoring committee was not felt necessary. No interim analysis of data is planned.  23 
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Harms 1 
The risks of nose and throat swabs and additional blood tests being taken are minimal and where 2 
occurring are likely to be mild. No additional adverse events s related to POCT for respiratory viruses 3 
are anticipated. However active monitoring and reporting of severe adverse events will be 4 
undertaken. Serious adverse events (SAE) are defined here as:  5 
 Death during admission or within 30 days of enrolment 6 
 Admission to the intensive care unit 7 
 Evidence of prolonged hospital stay 8 
 New or persistent significant disability or incapacity 9 
 Evidence of congenital anomaly or birth defect 10 
As participants in ED are not yet hospitalised but have a reasonable likelihood of being admitted to 11 
hospital, patients enrolled in ED who are subsequently admitted to the hospital will not 12 
automatically be counted as having experienced a SAE. Participants who are already admitted to 13 
AMU are already hospitalised however, an adverse event leading to prolongation of their existing 14 
hospitalisation will be counted as an SAE. 15 
Auditing 16 
Regular monitoring will be performed according to ICH GCP by the sponsor. Data will be evaluated 17 
for compliance with the protocol and accuracy in relation to source documents. Following written 18 
standard operating procedures, the monitors will verify that the clinical trial is conducted and data 19 
are generated, documented and reported in compliance with the protocol, GCP and the applicable 20 
regulatory requirements. 21 
Protocol amendments 22 
20 
 
All protocol modifications were communicated to investigators and to trial registries. Two 1 
amendments to the protocol have been approved by the ethics committee, the first, to change the 2 
study from a pilot study into a full study and to amend an exclusion criterion, the second, to add a 3 
laboratory analysis plan for the samples collected (current protocol version 3.0, date 26th January 4 
2016). The local study reference is RHM MED1217.  5 
Confidentiality 6 
All data will be anonymised to protect participant confidentiality: volunteer participant data will be 7 
identified by a unique study number in the case report forms and database. Serious Adverse Events 8 
will be reported in line with Good Clinical Practice and regulatory requirements. All study staff are 9 
trained in Good Clinical Practice. Only the investigators and sponsor’s representative (monitor) have 10 
access to the data, which is kept securely. 11 
Access to data 12 
The final data set will be wholly accessible to the principal investigator, co-investigators and 13 
independent statistician and may be made available to other parties on request.  14 
Dissemination policy 15 
Authorship of this and subsequent manuscripts stemming from this protocol will follow the ICMJE 16 
recommendations, and CONSORT statement where appropriate, and there is no intent to use 17 
professional writers. There are no plans to make the dataset publically available. Beyond the study 18 
team and regulatory oversight, the full protocol is only made available at the discretion of the chief 19 
investigator. The data and samples collected are expected to form multiple publications, and these 20 
publications must acknowledge this trial and study team as appropriate. 21 
DISCUSSION 22 
21 
 
This study has the potential to improve patient care by changing practice and contribute to a health 1 
economic analysis. The outcome measures are clinically important to a large number of patients, and 2 
also crucial in antimicrobial stewardship and healthcare resource management. As a randomised 3 
controlled trial, this study will provide high-quality evidence for the potential use of molecular point-4 
of-care testing for respiratory viruses in hospitalised adults. Beyond this trial, molecular point-of-5 
care testing for common pathogens in select populations, such as in intensive care, or other 6 
common illness presentations, such as gastroenteritis, needs to be evaluated to further improve 7 
patient care and effectively manage healthcare resources. 8 
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